Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37977
Title: Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics
Authors: MULLENS, Wilfried 
DAUW, Jeroen 
Martens, Pieter
MEEKERS, Evelyne 
NIJST, Petra 
VERBRUGGE, Frederik 
Chenot, Fabien
Moubayed, Samer
Dierckx , Riet
Blouard, Philippe
Derthoo, David
Smolders, Walter
Ector , Bavo
Hulselmans, Michael
Lochy, Stijn
Raes , David
Van Craenenbroeck, Emeline
Vandekerckhove, Hans
Hofkens, Pieter-Jan
Goossens, Kathleen
Pouleur, Anne-Catherine
De Ceuninck, Michel
Gabriel, Laurence
Timmermans, Philippe
Prihadi, Edgard A.
Van Durme, Frederik
Depauw, Michel
Vervloet, Delphine
Viaene, Els
Vachiery, Jean-Luc
Tartaglia, Katrien
Ter Maaten, Jozine M.
BRUCKERS, Liesbeth 
Droogne, Walter
Troisfontaines, Pierre
Damman, Kevin
Lassus, Johan
Mebazaa, Alexandre
Filippatos, Gerasimos
Ruschitzka, Frank
DUPONT, Matthias 
Issue Date: 2022
Publisher: WILEY
Source: European journal of heart failure,
Status: Early view
Abstract: Aims To describe the baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial and compare these with other contemporary diuretic trials in acute heart failure (AHF). Methods and results ADVOR recruited 519 patients with AHF, clinically evident volume overload, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) and maintenance loop diuretic therapy prior to admission. All participants received standardized loop diuretics and were randomized towards once daily intravenous acetazolamide (500 mg) versus placebo, stratified according to study centre and left ventricular ejection fraction (LVEF) (<= 40% vs. >40%). The primary endpoint was successful decongestion assessed by a dedicated score indicating no more than trace oedema and no other signs of congestion after three consecutive days of treatment without need for escalating treatment. Mean age was 78 years, 63% were men, mean LVEF was 43%, and median NT-proBNP 6173 pg/ml. The median clinical congestion score was 4 with an EuroQol-5 dimensions health utility index of 0.6. Patients with LVEF <= 40% were more often male, had more ischaemic heart disease, higher levels of NT-proBNP and less atrial fibrillation. Compared with diuretic trials in AHF, patients enrolled in ADVOR were considerably older with higher NT-proBNP levels, reflecting the real-world clinical situation. Conclusion ADVOR is the largest randomized diuretic trial in AHF, investigating acetazolamide to improve decongestion on top of standardized loop diuretics. The elderly enrolled population with poor quality of life provides a good representation of the real-world AHF population. The pragmatic design will provide novel insights in the diuretic treatment of patients with AHF.
Notes: Mullens, W (corresponding author), Ziekenhuis Oost Limburg, Schiepse Bos 6, B-3600 Genk, Belgium.
wilfried.mullens@zol.be
Keywords: Acute heart failure;Belgium;Diuretics;5 Grand Hôpital de Charleroi, Charleroi, Belgium;Randomized controlled trial;6 CHU Charleroi, Charleroi, Belgium;7 OLV Hospital, Aalst, Belgium;Acetazolamide;Congestion;8 Clinic Saint-Luc, Bouge, Belgium;Volume overload;9 AZ Groeninge, Kortrijk, Belgium;10 AZ Klina, Brasschaat, Belgium;11 Imelda Hospital, Bonheiden, Belgium;12 Ziekenhuis Maas en Kempen, Maaseik, Belgium;13 GZA Sint-Augustinus, Wilrijk, Belgium;14 Belgium;16 AZ Sint-Lucas, Ghent, Belgium;17 AZ Turnhout, Turnhout, Belgium;18 AZ Nikolaas, Sint-Niklaas, Belgium;19 Cardiovascular Department, Cliniques Universitaires St Luc, Brussels, Belgium;20 AZ Delta, Roeselare, Belgium;21 CHU UCL Namur, Yvoir, Belgium;22 Jessa Hospital, Hasselt, Belgium;23 ZNA Hartcentrum, Antwerpen, Belgium;24 AZ Glorieux, Ronse, Belgium;25 Universitair Ziekenhuis Gent, Ghent, Belgium;26 AZ Maria Middelares, Ghent, Belgium;27 Jan Yperman Hospital, Ieper, Belgium;28 Ziekenhuis Erasme, Brussels, Belgium
Document URI: http://hdl.handle.net/1942/37977
ISSN: 1388-9842
e-ISSN: 1879-0844
DOI: 10.1002/ejhf.2587
ISI #: 000822982700001
Rights: 2022 European Society of Cardiology
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR)_ baseline characteristics.pdf
  Restricted Access
Published version1.42 MBAdobe PDFView/Open    Request a copy
Show full item record

WEB OF SCIENCETM
Citations

19
checked on Mar 29, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.